CHRS · Coherus Oncology Inc
United States · RS rating 9 · As of 2026-10-14
| Price | 1.05 USD |
|---|---|
| 1-day change | -1.9% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 11 / 15 / 18 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 17 / 18 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | +10.2% |
| Distance from 52-week high | +58.2% |
| Market cap (USD) | $263.8M |